Can Genetic Research Involvement Motivate Parents to Pursue CMA Genetic Testing for Children with Autism Spectrum Disorder? by Floyd, Augustus Evander
CAN GENETIC RESEARCH INVOLVEMENT MOTIVATE PARENTS TO PURSUE CMA 
GENETIC TESTING FOR CHILDREN WITH AUTISM SPECTRUM DISORDER? 
by 
Augustus Evander Floyd 
 
A Senior Honors Project Presented to the 
Honors College 
East Carolina University 
In Partial Fulfillment of the 
Requirements for 
Graduation with Honors 
By 








Lei Xu, PhD. 
Health Education and Promotion 
College of Health and Human Performance 
Floyd 2 
Introduction 
Autism spectrum disorder (ASD), a neurodevelopmental condition characterized by 
impaired social behavior and restricted interests, continues to present (Heil & Schaaf, 2013).  
According to the newest autism prevalence estimate (Autism and Developmental Disabilities 
Monitoring) by the Centers for Disease Control and Prevention (CDC), one in every 68 children 
in the United States has been diagnosed on the spectrum (CDC, 2014).   The prevalence of ASD 
increased roughly 123% from 2002 to 2010, but has remained unchanged between 2010 and 
2012.  This report also suggests that while a large margin of parents of children with ASD have 
concerns about their children’s medical or educational records, less than half of these children 
receive developmental evaluations or diagnosis prior to age 3 (CDC, 2014). 
While the etiology of ASD is still uncertain, the existence of a connection to genetic 
disorders is attested by a body of findings (Heil & Schaaf, 2013).  ASD is found to be highly 
heritable, with the risk of a parent of a child with ASD having another child being affected by 
ASD being 7% if the first child is female and 4% if the first child is male (Schaefer & 
Mendelsohn, 2013).  If multiple children have ASD, the risk of recurrence is estimated to be 
between 33–50% (Miller et al., 2010; Schaefer & Mendelsohn, 2013).  Currently, chromosomal 
disorders such as Fragile X and Down’s Syndrome have been identified as comorbid for ASD 
(Shen & Miller, 2014).  However, it is believed that roughly half of ASD genetic causes involve 
de novo, or non-syndromic, mutations (Bauer & Msall, 2011).  Of these, 8-21% of autism-linked 
genetic disorders exist in the form of a varying degree of point mutations known as copy number 
variants (CNVs) (Carter & Scherer, 2013; Heil & Schaaf., 2013).  Genes that are considered 
CNVs for ASD can affect multiple points across numerous portions of the genome (Carter, M., 
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& Scherer, 2013).  The variety of distances and number of CNVs are believed to be related to the 
complex range of phenotypes appearing on the autism spectrum (Heil & Schaaf, 2013). 
Chromosomal microarray analysis (CMA) has been reaffirmed by the 2013 revision 
guidelines of the American College of Medical Genetics (ACMG) as a first-tier genetic test for 
neurodevelopmental disorders, including ASD (Miller et al., 2010; Toruner, Dermody, & Tolias, 
2012; Bauer & Msall., 2011).  In this tiered approach, CMA is recommended as the first test for 
developmental disorders such as ASD.  The diagnostic yield through CMA is found to be 15-
20% in most studies, as well as almost 30% by prior screening with complex cases (Shen & 
Miller, 2014).  In this procedure, a blood sample is taken from the patient, and the genetic 
material is then comprehensively scanned in comparison to a healthy genome control (Jiang et 
al., 2014).  In identifying distinct variants from the control, this reveals mutations that may be 
related to the development of ASD in the patient (Toruner, et al., 2012).  
The value of the results of CMA to ASD patients and caregivers in identifying these 
CNVs is outlined by the 2013 revised consensus statement of the AMCG (Schaefer & 
Mendelsohn, 2013).  Obtaining a usable genetic diagnosis for autism is suggested to parents of 
affected children due to the possibility to influence treatment, management, and decision-making 
for family planning (Miller et al., 2010; McGrew, Peters, Crittendon, Veenstra-Vanderweele, 
2012; Cuccaro et al., 2014).  In addition to its prospective uses for those receiving the test, 
another outcome of undergoing CMA for neurodevelopmental disorders is this information’s 
potential role to advance autism research (Miller et al., 2010; Schaefer & Mendelsohn, 2014). 
In the 2010 consensus statement of AMCG, the use of genomic databases was 
recommended to increase the utility of findings from genetic tests.  One such example was 
DECIPHER (Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl 
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Resources) hosted by the International Standard Cytogenic Array Consortium, which served as 
an as online password-protected storage system of genetic tests results (Firth et al., 2009; Miller 
et al., 2010.  A more recent example that is specifically focused specifically on autism genomic 
results is SFARI Gene 2.0 organize by the Simons Foundation (Abrahams et al., 2013).  
Platforms such as these are designed to share and present data from genetic testing patients 
among researchers (Miller et al., 2010).  Professionals involved with this project can analyze a 
bank of test results recorded from patients to identify previously unidentified mutated genes 
which may contribute to the cause of ASD and other genetic disorders (Miller et al., 2010; Shen 
et al., 2014).  By identifying and recording new candidate genes, the genetic causes that underlie 
ASD can be more accurately described and more greatly understood (Asadollahi et al., 2014).  
Thus far, the collection of this data has been useful in detecting and describing new CNVs, 
which can ultimately influence future diagnosis and treatment (Battaglia et al., 2013; 
Oikonomakis et al., 2016).  However, further elucidation of suspected genetic components of 
ASD can only be driven by the contributions of results obtained from genetic testing data of 
affected individuals. 
Parents can be regarded as the primary caregivers of children suffering from ASD and 
thus the main rational actor in testing decision making.  When the phenotype of autism is 
diagnosed and is ruled to likely have an uncertain cause, genetic testing can be advised by a 
healthcare professional, typically the patient’s pediatrician (Carter & Scherer, 2013; Jiang et al., 
2014).  Concerning the levels of parent interest, studies have consistently found that supportive 
attitudes to pursue genetic testing are high (Narcisa et al., 2013; Trottier et al., 2013; Chen, 
Huang, & Dhar, 2013; Amit, Couchon, Carr, Carayol, & Cohen, 2014).  Despite positive 
perceptions as well as the potentially beneficial outcomes of a genetic diagnosis, actual 
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utilization of CMA among other genetic testing options are reported as being low among parents 
of children with ASD (Cuccaro et al., 2014; Peabody et al., 2016; Vande-Wydeven, Kwan, 
Hardan, & Bernstein 2012; Amiet, Couchon, Carr, Carayol, & Cohen, 2014; Selkirk, McCarthy-
Veach, Lian, Schimmenti, & Leroy, 2009).  
One possible factor of intention toward receiving CMA testing is the prospect of 
contribution to the genomic databases used in research, such as SFARI Gene 2.0.  Regarding this 
outcome of testing, decision by parents to have a biological offspring undergo CMA may 
represent a form of participation in autism genetic research.  Parent perceptions toward using 
their ASD-affected child’s information in genetic research has been previously been found to be 
overall positive (Johannesen et al., 2016).  Due to this information being passed on for study 
within a genomic resource for the use of researchers, electing to participate in research using 
CMA results can be considered an altruistic motivation.  Throughout studies of autism genetic 
research, altruism is found as a consistent motivator (Trottier, et al. 2013; Singh, 2015; 
Johannesen, et al., 2016).  For the Simon’s Simplex Collection, it was discovered that at least 
two-thirds of parents participated to altruistically contribute to autism research (Singh, 2015).  
Trottier et al. (2013) found in an exploratory study that participation was motivated by an 
amalgam of both personal interest and altruism. 
Previous studies have shown contributing to research motivates genetic testing intention 
among tests for a variety of conditions.  Exploratory and pilot studies have identified furthering 
research as among the primary reasons given for testing for genetic causes of sudden cardiac 
death, smoking susceptibility, deafness, and a variety of cancers (Boudreault et al., 2010; 
Giordimaina, Sheldon, & Petty, 2014; Hallowell et al., 2010; Erskine, et al. 2014; Esplen et al., 
2001).  For quantitative studies involving genetic tests for conditions including BRCA, 
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Alzheimer’s, and pancreatitis, testing intention has previously been associated with wanting to 
help advance research (Roberts et al., 2003; Phillips et al., 2000; Applebaum-Shapiro, Peters, 
O’Connell, Aston, & Whitcomb, 2001; Geller, Doksum, Bernhardt, & Metz, 1999).  Regarding 
genetic testing for a variety of psychiatric disorders, a questionnaire-based study also found that 
positive belief in genetic researchers to use this information to advance knowledge was also 
associated with participants’ intention to undergo genetic testing (Laegsgaard, Kristensen, & 
Mors, 2009).  Because desire to help with research motivates intention to test for other genetic 
disorders, this may also be true for intention regarding genetic tests for ASD.  Despite this trend 
among other conditions as desire to pursue genetic testing as being motivator, cross-sectional 
studies have recommended that each test be properly assessed for its own factors of motivation 
and parameters that determine parents’ perceptions of testing (Holly, 2011; Sweeny, Ghane, 
Legg, Huynh, & Andrews, 2014).  To date, no available quantitative studies have measured the 
intention to test an ASD-affected child as it is associated with desire to help with research or 
perspectives about research. 
Recently, several qualitative studies have been conducted to measure parents’ intention in 
genetic testing for ASD, two of which were hypothetical studies focused on CMA (Reiff, 
Bernhardt, & Easley; Xu, Mitchell, Richman, & Clawson, 2016; Chen, Xu, Huang, Shweta, & 
2013).  Each has included parents’ responses that suggest an interest in testing based on an 
acknowledgement of its use in ASD genetic research and desire to help advance these efforts.  In 
a sample performed on an underserved population, desire to help with research was among most 
prominent items mentioned (Xu et al., 2016).  While impact of altruism to help advance research 
on ASD features as a reason that parents would test, the relationship between testing and this 
altruistic motivation has not been documented.  Information is needed to fill the gap regarding 
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the extent of this factor as a motivator for genetic testing intention among parents of children 
with ASD. 
To better understand the relationship of desire to help with genetic research on autism and 
test intentionality, parents across Eastern North Carolina were surveyed about their perceptions.  
This sample was collected from the surrounding region from which Xu et al. (2016) previously 
detected desire to help with research as a motivator for interest in testing among parents.  This 
study sought to answer two questions: (1 Is interest in CMA genetic testing associated with 
parents’ desire to contribute to autism research? (2 Does perception about the impact of testing 
on autism research relate to parents’ CMA intentionality? 
Methodology 
 Participants 
Those involved with the study were required to be the biological parents of at least one 
currently living child with autism.  Participants were also required to be residents in one of the 
44 counties in Eastern North Carolina.  Age was necessitated at 18 years old, however age of the 
child of the participants with ASD was not restricted.  English literacy was also required to read 
and complete the survey. 
Design and Recruitment 
This study was a component of a larger interactive online survey distributed by email.  
The survey was designed by a panel of experts using instruments found from questionnaire-
based studies which previously measured genetic testing perceptions, motivators, and barriers.  It 
was then revised based upon revision sessions among the panel and the suggestion of a focus 
group of parents of children with autism, which included 20 members who were one-on-one 
interviewed.  The completed 44-item instrument was uploaded to the online survey platform 
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Qualtrics for parents to complete through convenience sampling.  The link to complete the study 
was distributed to parents of children with autism through email contact to advocacy 
organizations within the designated 44 counties of Eastern North Carolina.  These were located 
by online listing, social media presence, and personal contact.  In several instances, a paper 
survey was hand-delivered to participants in the local community and subsequently collected.  
Participation and successful completion of the survey was incentivized by a $20 Walmart gift 
card.  
Outcome Variables 
Regarding the survey’s sample, demographic factors were taken of the sample.  These 
measures included race, gender, average age, household income, and level of education.  
The primary outcome variable was based on whether the parent would hypothetically 
take the child to receive genetic testing, which was coded as the dependent variable.  In the 
survey, participants (parents) were asked the likelihood of them taking their child to a genetic 
testing for autism if recommended by a healthcare professional.  Responses were measured on a 
four-point Likert scale which ranged “A great deal,” “Somewhat,” “Slightly,” and “Not at all.”  t 
was coded Yes (1) if a participant responded, “A great deal” or “Somewhat”, and No (0) was 
entered if a participant responded “Slightly” or “Not at all.”  
The other outcome variables were parents’ motivation and three perceptions toward ASD 
genetic testing.  These were coded as four dependent variables.  For parents’ motivation 
involving helping with ASD research, the section was prefaced with the instructions “Please 
check whether the following factors would affect your decision-making” The response item 
“desire to help with research” was included to represent research as a possible reason to pursue 
genetic testing.  Responses were measured on a Likert Scale which ranged “Very likely,” 
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“Likely,” “Unlikely,” and “Very unlikely.”  It was coded Yes (1) if a participant responded, 
“Very likely” or “Likely”, and No (0) was entered if a participant responded “Unlikely” or “Very 
unlikely”. 
To represent parents’ perception about the relationships of genetic testing outcomes and 
ASD genetic research, three items were included in the survey.  These items were prefaced with 
the instruction for the participant to “Please check whether you agree or disagree with the 
following statements:”.  Each sentence was based upon prior qualitative findings about parent 
perceptions of research outcomes related to genetic testing of their children.  The first measure 
was based on positive belief about the influence of genetic testing upon ASD research, which 
stated “Genetic testing can positively impact autism research.”  The second was of positive belief 
about the personal outcomes of ASD research, which stated: “Genetic Research improves my 
child’s quality of life.”  The third was a negative perception about the personal outcomes of ASD 
genetic testing regarding ASD research which stated: “Genetic testing would only be beneficial 
for autism research.”  Responses were measured on a four-point Likert scale which included 
“agree.”  For each statement, a “1” was recorded if the participant answered, “strongly agree” or 
“agree”; a “0” was recorded if the participant answered, “disagree” or “strongly disagree”.  
Statistical Analysis 
Frequency tables were used to measure the demographic variables of the sample.  
Fisher’s exact test and odds ratio was used to compare outcome variables examined in this study.  
This was done to assess the association between intention to test and responses related to both 
desire to assist with ASD research and perceptions about genetic research.  Analyses were 

















Descriptive statistics of the sample are presented in Table 1.  A total of 204 (N=204) 
participants completely responded to all questionnaire items related to this study, 181 female and 
23 male.  All were parents of children with autism living in Eastern North Carolina.  Majority of 
the participants were Caucasian and female.  Most had completed some college and had a family 




Table I: Demographic Characteristics of Parents (N = 204) 
Characteristic  Percentage 
Gender   
 Male 11.87 
 Female 88.7 
Ethnicity   
 Caucasian 74.5 
 Black/African American 12.7 
 Native American 7.4 
 Hispanic 2.5 
 Other/Mixed 2.9 
Education Level   
 Did not Finish High School 2.5 
 High School or GED 11.8 
 Associate’s Degree or Some College 45.6 
 Bachelor’s Degree 25.0 
 Master’s or Professional Degree 15.2 
Income   
 <$20,000  13.2 
 $25,000 - $39,999 20.6 
 $40,000 - $59,999 25.5 
 $60,000 - $75,000 14.2 
 >$75,000 25.5 
 Other 1.0 
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their children to receive ASD genetic testing (Table I).
 
Figure I is a subset pie chart which displays the subdivision of those who desire to 
contribute to research within those who would likely test.  The figure also provides an 
association between desire to help with research and likelihood to test their child (p = 0.032*) as 
determined by Fisher’s exact test as well as with an odds ratio of 2.62. 
Table II: Association of Likelihood to Test Children and Perceptions of Research (N = 204) 
Please check whether you agree or disagree with the following 
statements: 
           p value* odds ratio 
“Genetic testing can positively impact autism research” 0.001* 13.0 
“Genetic research improves my child’s quality of life” 0.002* 3.63 
“Genetic testing would only be beneficial for autism research, 
not me or my family”  
0.340 0.676 





Figure I: Association of Likelihood to Test Children and Desire to 
Help with Research (N = 204)
Likely to Test
Unlikely to Test Desire to Help




The relationship between likelihood to test and perceptions about ASD research was 
measured in Table II.  The text of the item is displayed along with the outcome of Fisher’s test as 
well as the odds ratio measured.  For perception about genetic testing benefiting autism research, 
this item was found significantly associated at P value of 0.001.  The odds ratio was also found at 
a likelihood of 13.0.  For the relationship between decision to test a child and belief that autism 
genetic testing favorably impacts the child’s quality of life, these two measures were also 
significantly associated with a p-value of 0.002.  The odds ratio was also measured at 13.0. 
Regarding parental belief that genetic testing would only beneficial to research, this result would 
not be significantly associated, with a p-value of .340.  The odds ratio that was presented was 
also found to be .676.  
Discussion 
 This study provides insight about the possible decision making of parents of children 
with autism when pursuing genetic testing.  The intention of parents within our study to have 
their children receive testing was found relatively high at 84.3%, which suggests that majority of 
participants are likely to consider having their ASD-affected child undergo CMA.  This number 
is consistent with existing findings about the level of parent interest toward ASD genetic testing 
across quantitative studies, which ranged from 80% to 86% (Cuccaro et al., 2014; Amiet et al., 
2014; Narcissa et al., 2012).  While not exclusively for genetic testing, Vande Wydeven et al. 
(2012) also found parent interest in utilizing genetic services at 90%.  For CMA specifically, 
quantitative studies have found among samples 69% and 85% (Chen et al., 2013; Xu et al. 2016).  
The high intention to test measured in this study furthers the need to investigate factors that are 
considered important by parents related to testing decision, particularly for use in elucidating 
reasons for low CMA uptake in the clinical setting. 
Floyd 13 
Most significantly, parental intention toward CMA genetic testing of their children within 
this study was associated with the prospect of contributing to research.  This highlights that this 
factor, which has been consistently described in qualitative studies on parent perception about 
CMA could indeed be predictive of test intention (Chen et al., 2013; Reiff et al., 2015; Xu et al., 
2016).  The finding that increase in intention to test is associated with desire to support research 
corroborates existing data with similar findings from quantitative studies about genetic testing 
intention (Roberts et al., 2003; Phillips et al., 2000; Applebaum-Shapiro et al., 2001; Geller et 
al., 1999).  However, these studies represent findings on personal motivation for genetic testing 
rather than for that involving another family member, such as a biological child.  While 
participants were not answering for a testing decision involving themselves, this provides further 
evidence of genetics research advancement as a motivator for genetic testing intention.  These 
results represent the first quantitative findings for an ASD genetic test that considers research 
contribution as a factor of intention for genetic testing of a child. 
Moreover, within this study, decision-making is also shown be partly influenced by 
expectations about testing outcomes on ASD research.  Data from this study partly supports 
statements made by parents of children with ASD in previous exploratory studies about CMA 
perceptions.  Intention increased with belief that genetic testing could advance ASD research, as 
was brought up by parents in existing studies (Chen et al., 2013, Reiff et al., 2015; Xu et al. 
2016).  Intention also increases with belief that assisting these efforts would improve their ASD 
child’s “quality of life.”  It was hoped that research would offer their child additional support at 
some future point by parents that Reiff et al., (2015) interviewed.  However, negative attitudes 
about genetic testing for ASD, such as that testing outcomes would not be personally helpful, 
was challenged by lack of significance of this response item (Xu et al., 2016).  This data would 
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suggest that greater parental belief and positive value of the outcomes of the elements 
surrounding testing could serve as a motivator for testing intention.  This would also indicate that 
negative perceptions about outcomes do not have a direct impact on hypothetical parental 
decision for genetic testing. 
Given that parents have demonstrated that genetic research is potentially a factor in test 
decision, health education studies have yet to explore possible value in affecting intention among 
parents.  Enhancing knowledge and formation of beliefs on this subject may have a different 
effect on hypothetical testing decision beyond awareness.  For this effort, it is necessary that 
educational interventions that can demonstrate the change of intention through providing 
information about research efforts through genetic testing for ASD. 
Conclusion 
The implications of this study inform existing data on parental intention about genetic 
testing for ASD.  Our results demonstrate an association between beliefs and motivations 
surrounding ASD research and testing decision, which at this point have not been assessed 
outside of qualitative findings.  The possible outcomes of receiving positive information about 
research upon genetic testing intention are thus indicated by this study.  Parents may wish to test 
their ASD-affected child at least partially because they want to advance research, they perceive 
in genetic testing their child benefits research, or because they believe research developments 
enhance the prospects of their children.  Conversely, this study demonstrates that negative 
perceptions about genetic research outcomes from testing, such as that they are not personally 
useful, do not impact testing intention of parents.  This would indicate that negative assessments 
not be a factor in decision alongside positive assessments of outcomes related to genetic 
research.  Since unfavorable perceptions can be negated, it could thus be expected that providing 
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information related to the role of genetic testing in ASD research would have a positive impact 
on testing intention of parents.  
Especially because research contribution is an outcome not immediately experienced by 
parents in having their child undergo CMA, the worth of these findings is predicated on 
explaining this aspect of testing to parents.  It could be recommended that current methods of 
patient education be modified to incorporate sufficient material about ASD research prospects.  
Health educators seeking to inform parents about genetic testing for ASD should include details 
within programs about the prospects of CMA to benefit DECIPHER, DGV, and other genomic 
resource endeavors within ASD research.  In the clinical setting, both physicians and genetic 
counselors should consider the aspect of assisting genetic research within their support provided 
to parents of patients referred for advanced-level ASD genetic testing.  By providing sufficient 
information about all considerations related to testing decision, professionals can more 
effectively direct their guidance and support offered to families about CMA.  By supporting 
parent understanding of this endgame outcome for their child’s procedure, this can be expected 
to increase their likelihood to pursue genetic testing.  With greater awareness about this 
possibility, parents will be able to make a more informed decision about their utilization of 
genetic services and in doing so potentially advance efforts to better understand ASD.  
Limitations 
Several factors limit the capabilities of this study’s findings.  For one, accuracy of 
information collection may be lowered through use of an online survey.  Responses were under 
the assumption that respondents were in fact parents of children with autism residing in the 
designated counties of Eastern North Carolina.  This study’s validity was also dependent on 
participants answering each question honestly and carefully to reflect their true beliefs.  The 
Floyd 16 
survey was also relatively long and items related to this study were not all located in the same 
section.  In that respect, the responses could have reasonably been skewed and biased upon 
mental state and level of focus through each portion of the survey.  Parents also provided 
responses from a hypothetical scenario of genetic testing and may not represent a participant’s 
views during actual testing experience.  
Through participant recruitment, the study also did not produce a diverse sample.  
Despite a higher area of income inequality and racial diversity within the area of recruitment, 
majority of active members of contacted parent organizations were considerably comprised of 
Caucasian mothers of mid-level SES.  Incidentally due to our recruiting method, the 
demographics of those taking the survey were skewed toward middle income, middle education, 
Caucasian, and female.  This may lower the generalizability of this study toward parents of 
minority backgrounds or lower SES. 
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